Under construction – not a live service
Sign in
Taking people in ChinaEarly phase 1

PET/CT Scan Imaging Test for Breast, Prostate and Brain Tumors

Tests a new radioactive imaging agent to find tumors in adults with cancer.

Plain-language title generated from the registry record
Registry title: 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients

Key facts

Where
Beijing, ChinaSee the site
Phase
Early phase 1

Where in China

  • Peking Union Medical College HospitalBeijing, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Peking Union Medical College Hospital
Trial code
NCT05549024
Record updated
5 July 2024
Original description
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.Read full original descriptionShow less

68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients

Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.

Inclusion: patients with confirmed or suspected breast/brain/prostate cancer; 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET/CT within 2 week; signed written consent.

Exclusion: any medical condition that in the opinion of the investigator may significantly interfere with study compliance; pregnancy; breastfeeding.

ClinicalTrials.gov NCT05549024